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Abstract: Several stimuli can change maternal hormone levels during pregnancy. These changes
may affect trophoblastic cells and modulate the development of the embryo and the placental tissue
itself. Changes in cortisol levels are associated with impaired trophoblast implantation and function,
in addition to other pregnancy complications. This study aims to analyze the effects of low and high
doses of cortisol on an extravillous trophoblast cell line, and the effects of various exposures to this
hormone. SGHPL-4 cells were treated with cortisol at five doses (0–1000 nM) and two exposures
(continuous: 24 h/day; and intermittent: 2 h/day). In intermittent treatment, cortisol acted mainly
as an anti-inflammatory hormone, repressing gene expression of kinin B1 receptors, interleukin-6,
and interleukin-1β. Continuous treatment modulated inflammatory and angiogenic pathways,
significantly repressing angiogenic factors and their receptors. Cortisol affected cell migration and
tube-like structures formation. In conclusion, both continuous and intermittent exposure to cortisol
repressed the expression of inflammatory genes, while only continuous exposure repressed the
expression of angiogenic genes, suggesting that a sustained increase in the levels of this hormone is
more harmful than a high short-term increase. Cortisol also impaired tube-like structures formation,
and kinin receptors may be involved in this response.
Keywords: cortisol; extravillous trophoblast; angiogenesis; cell migration; kinin receptors
1. Introduction
The placenta, a highly differentiated maternal–fetal organ intended exclusively for
offspring’s development, is a linking tissue between the mother and the fetus. Besides
being essential for embryo nutrition and development, it also acts as a barrier, preventing
high levels of hormones or other peptides from reaching the fetal circulation [1,2]. During
placental development and in a sequence of complex events, cytotrophoblast cells differ-
entiate into multinucleated syncytiotrophoblasts and also aggregate to form anchoring
villi [3], which will later give rise to extravillous trophoblasts (EVTs), with an invasive
phenotype [4,5].
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One of the main characteristics of EVTs is the ability to migrate into the maternal
spiral arteries and invade the venous and lymphatic vessels [6]. EVTs are responsible for
anchoring the placenta in the uterus and for the invasion of uterine vessels [7]. Changes
in their functions can lead to serious pregnancy complications, such as preeclampsia,
which presents shallow trophoblastic invasion and failure in vascular transformation [8–10].
The SGHPL-4 cell line represents EVTs, developed from the human placenta in the first
trimester of pregnancy [11,12] and is widely used in invasion and migration studies [13–17].
Additionally, the SGHPL-4 cell line has characteristics of normal EVTs and the invasive
capacity similar to primary EVTs [13] and has therefore been previously recommended as
an EVT model for in vitro studies [18].
In addition to the essential role of trophoblasts, several adaptations are required for a
pregnancy to be successful, and many of these physiological adjustments are driven by the
mother’s hormones [1]. Alterations in hormone or other peptides levels in the mother’s
blood can affect trophoblastic cells and modulate the development of both the embryo
and the placental tissue itself. Cortisol, the main glucocorticoid (GC), is one of the key
hormones for the maintenance and evolution of pregnancy [2] and for preparing the fetus
to the extrauterine life [19,20]. It is a hormone secreted in a pulsatile manner that follows
a circadian rhythm and is sensitive to environmental factors, such as light and darkness
periods, sleep, exercise, food deprivation, and diseases [21–23]. At adequate levels, this hor-
mone is essential for healthy gestational development, including the stimulation of human
chorionic gonadotropin (hCG) secretion, suppression of uterine natural killer cells [24],
and promotion of human leucocyte antigen-G (HLA-G) expression in trophoblasts [25].
Despite their important functions, exposure to synthetic glucocorticoids or physiologi-
cal stress during pregnancy has been negatively related to fetal development and pregnancy
complications [1,2,26–29]. Changes in cortisol levels have been associated with impaired tro-
phoblast implantation and function [30,31], including migration, proliferation and invasion
of EVTs [32], inhibition of cytokine-prostaglandin signaling, induction of apoptosis [24],
restriction of intrauterine growth [26,33], low birth weight, and preeclampsia [1,34].
Considering the importance of maintaining adequate hormone levels during preg-
nancy, there are mechanisms that protect the fetus from excess maternal GCs, such as the
enzymatic activity of 11-hydroxysteroid dehydrogenase type 2 (HSD11B2), which is crucial
for the metabolism of cortisol, transforming it into an inactive form [1,33,35]. When this
mechanism is not sufficient, cortisol levels can reach supraphysiological values over a
long period, thus promoting the aforementioned disorders [2,34]. The HSD11B2 enzyme
is found in placental cells. Initially, it is limited to syncytiotrophoblasts, and at around
10–12 weeks of pregnancy, this enzyme is also found in cytotrophoblasts and EVTs [36].
It is important to note that each trimester of human pregnancy has a specific inflamma-
tory profile: in the first trimester, cytokines such as interleukin-1β (IL1B) and interleukin-6
(IL6) are necessary for the implantation process and for proper EVT function [37,38], and the
lower levels of cortisol contribute to this, since it is a hormone with anti-inflammatory activ-
ities [26]. On the other hand, in the third trimester, baseline cortisol increases, contributing
to prevent pulmonary collapse through surfactant production and also contributing to the
induction of childbirth [39]. It is also worth noting that placental cells, including EVTs [40],
express a high level of glucocorticoid receptor (GR) [41], which is capable of responding to
changes in cortisol levels.
In human pregnancy, appropriate trophoblast implantation and proliferation is a
determining factor for the fetal and maternal outcome. Taking into account the actions
promoted by cortisol at both physiological and supra-physiological levels, as well as the
essential function of trophoblasts for gestational development, especially EVTs, little is
known about the effect of cortisol on these cells, as well as the effects of this hormone
on early pregnancy [24]. Thus, this study aimed to analyze the effects of treatment with
low and high doses of cortisol on SGHPL-4 cells, as well as the effects of continuous and
intermittent exposure to this hormone on gene expression and cellular function.
Biomedicines 2021, 9, 980 3 of 20
2. Materials and Methods
2.1. Cell Culture and Cortisol Treatment
The first trimester EVT cell line, SGHPL-4, a kind gift from Judith E. Cartwright (St.
George’s University of London, London, UK), was used. Based on its phenotypic and
functional characteristics, this cell line has been recommended as a cell model to study
EVT function in vitro [18]. The cells were cultivated in HAM’s F10 Medium (Biochrom
GmbH FG0715 with 1.2 g/L NaHCO3, 10 mg/L Phenol red, stable glutamine, and low
endotoxin) and supplemented with 10% of heat-inactivated fetal bovine serum (FBS) and
1% of penicillin-streptomycin (Thermo Fisher, Waltham, MA, USA) at 37 ◦C with 5% CO2
and 21% O2. All experiments were conducted considering optimal passage range for
SGHPL-4 (between cell passages 18 to 25) [18].
The cells were plated at a density of 1.2 × 105 cells/well in 6-well flat-bottom plates.
The next day, the medium was replaced by a starvation medium, with 0.5% FBS and
1% antibiotics. The cortisol (CORT; Sigma-Aldrich, St. Louis, MO, USA) used for treatments
was a ready-to-use solution prepared in 100% methanol (1 mg/mL). After 24 h starvation,
the cells were treated with 100, 250, 500, or 1000 nM cortisol in the culture medium. In the
control group, the volume of methanol (vehicle) used was the same volume of cortisol
applied in the highest treatment dose, and the control group appears in the result graphs
as “0 nM”. The doses chosen for treatment were equivalent to physiological cortisol levels
at baseline (100 and 250 nM), stress (500 nM), and supra-physiological dose (1000 nM) [24].
The cells were divided into 10 groups, 5 groups of “continuous” exposure, and
5 groups of “intermittent” exposure to cortisol. Continuous exposure was performed in
order to mimic a chronic increase in cortisol levels, while intermittent exposure simulated
conditions that increase the level of this hormone in a pulsatile/intermittent manner,
such as physical exercise or several other acute situations. Continuous exposure groups
received the cortisol doses 24 h/day, for 3 days, and intermittent exposure groups received
cortisol in the culture medium for 2 h/day, also for 3 days (Figure 1). Control groups were
treated only with the vehicle, without cortisol. The culture medium was changed daily in
all groups, in order to ensure the same handling process and also due to cortisol half-life.
After treatment, the cells were collected and stored at −80 ◦C until RNA extraction.
2.2. RNA Extraction and RT-qPCR
RNA was extracted with Trizol (#15596026, Thermo, Waltham, MA, USA) according
to the manufacturer’s instructions after processing the SGHPL-4 cells in a homogenizer
(FastPrep®-24, MP Biomedicals LLC, Irvine, CA, USA). The RNA quality and integrity were
assessed by electrophoresis and observation of the 260/280nm absorbance ratio detected
by nucleic acid spectrophotometer (NanoDrop 1000, Thermo Scientific, Waltham, MA,
USA). Complementary DNA (cDNA) was synthesized using cDNA Reverse Transcription
kit (#4368814, Thermo, Waltham, MA, USA) using random primers and following the
manufacturer’s instructions. The qPCR reaction was performed using 9ng of cDNA and
Hot FirePol Evagreen qPCR Mix, ROX (Solis Biodyne, #08-24-00001), 10 µL reaction volume
in QuantStudio5 equipment (Applied Biosystems). For primer designing, we used Primer3
(primer3.ut.ee; last accessed on 5 May 2021) and Primer Blast (ncbi.nlm.nih.gov/tools/
primer-blast/; last accessed on 5 May 2021). Heterodimers, self-dimers, and hairpins
were checked at https://www.idtdna.com/calc/analyzer/; last accessed on 5 May 2021.
The values were normalized to reference gene 18S and calculated using the 2−∆∆Ct method;
results are expressed as fold change of the control value. For qPCR, all samples were
analyzed in duplicate. The primers used in this study are shown in Table A1.
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Figure 1. Study design. The first trimester extravillous trophoblast cell line SGHPL-4 was divided
into 2 main groups: “continuous” and “intermittent” exposure to cortisol. Each of these groups was
divided into another 5 groups according to the cortisol dose (0, 100, 250, 500, or 1000 nM). The cells
were plated on the first day, and the next day, the medium was replaced with one with only 0.5% FBS
(fasting). After 24 h starvation, the cells were treated with cortisol (a ready-to-use solution prepared
in 100% methanol) in the culture medium, and the control cells were supplemented with the same
volume f methanol (vehicle). Continu us expos re groups received the cortisol doses 24 h/day,
for 3 day , and intermittent exposure groups received cortisol in the culture medium for 2 h/day,
also for 3 days. The culture medium was changed daily.
2.3. MTT—Cell Proliferation Assays
In order to measure the cell proliferation rate and cell viability, a colorimetric MTT
assay was performed. For this experiment, 1 × 103 cells were added to 100 µL of medium
in each well of a 96-well microplate and cortisol treatments were carried out as described
in item 2.1 of this manuscript. The doses chosen for this experiment were 0 (control),
250, 500, and 1000 nM cortisol in a continuous exposure (24 h/day, for 3 days). The next
day, a MTT assay was performed as previously reported [42], with some adaptations, as
described below.
For the MTT assay, 10 µL of the 5 mg/mL MTT reagent (Thiazolyl Blue Tetrazolium
Bromide, Sigma-Aldrich, St. Louis, MO, USA) were added to each well of a 96-well
microplate and incubated at 37 ◦C for 6 h. After this period, when the intracellular punctate
purple dye was clearly visible under the microscope, 100 µL of dimethyl sulfoxide (DMSO)
were added to all wells. After a 20 min incubation at room temperature, the absorbance
was measured at 570 nm wavelength under an automatic microplate reader. In this assay,
the optical density is proportional to the number of living cells.
2.4. ound ealing ssay
he wound healing assay is a standar in vitro technique used to evaluate cell migra-
tion. Usi g a pipette ti , a cell-free area is created in a confluent monolayer of SGHPL-4
cells, in ord r to see whether the exposure to the cell-free area would induce these cells to
migrate into the ap, as previously de cribed [43]. The cells were injured u ing sta dard
p200 pipette tips, and after removing the medium, the wells were washed once with PBS,
and medium was replaced with one containing the respective cortisol treatment. This tro-
phoblast cell line was treated with cortisol (250, 500, and 1000 nM) and compared to control
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(cortisol-free medium). The experiment was carried out three times. Photos and measure-
ments were taken after 48 h of exposure. The cell-free areas at 0h and 48h time-points were
quantified by Image J as pixels and expressed as wound healing closure (%) [43].
2.5. Tube-Like Formation Assay
Tube-like formation assay was performed with SGHPL-4 cells as previously de-
scribed [44]. First, 10 µL of Matrigel (Corning™ Matrigel™-Corning, NY, USA) were
pipetted into each well of a 15-well plate (µ-Slide Angiogenesis–Ibidi) and incubated for
30 min at 37 ◦C with 5% CO2.
Then, the cells were plated (8 × 103 cells/well diluted in 50 µL of medium with
2% of FBS and 1% of antibiotics) on coated wells in the presence or absence of cortisol
(500 nM) and/or 1 µM of Des-Arg9-Bradykinin (DBK), a kinin B1 receptor agonist. After 5 h,
the wells were observed under inverted phase contrast microscope (Zeiss, Jena, Germany).
The number of branching points, tubes, and loops was quantified with the WimTube
Software (Wimasis, Munich, Germany) considering the counts per image derived from
independent experiments (n = 4) performed in triplicate. A pilot experiment was carried
out to standardize the assay (Figure A1).
2.6. Statistical Analyses
GraphPad Prism 7 for Mac OS X, version 7.0a, 2 April 2016 was used for statistical
analyses. Data are shown as mean ± standard error of the mean (SEM). Data were com-
pared by one-way ANOVA or two-way ANOVA followed by Tukey multiple comparisons
test. Statistical significance was considered for p < 0.05 (GraphPad Software, La Jolla, CA,
USA, www.graphpad.com, accessed on 10 May 2021).
3. Results
3.1. Continuous Treatment Represses NR3C1 Gene without Modulations in HSD11B2
All four cortisol doses of continuous treatment were able to repress the expression
of NR3C1, the glucocorticoid receptor gene for up to 30%: 100 nM: p < 0.05; 250, 500 and
1000 nM p < 0.0001 (Figure 2A). No modulation was observed with intermittent treatments
(Figure 2A). The expression of the HSD11B2 gene, which encodes the enzyme responsible
for cortisol inactivation, was not modulated by any dose of both treatments (Figure 2B).
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Figure 2. Glucocorticoid receptor and HSD11B2 enzyme gene expression. RT-qPCR of NR3C1 (A) and HSD11B2 (B) in 
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Figure 2. Glucocorticoid receptor and HSD11B2 enzyme gene expression. RT-qPCR of NR3C1 (A) and HSD11B2 (B) in
SGHPL-4 cells treated with continuous or intermittent exposure to cortisol (100, 250, 500, 1000 nM) and vehicle (0 nM) in the
medium. Data were compared by two-way ANOV with Tukey multiple comparisons test. Interaction between (continuous
or intermittent) exposur to cortisol and cortisol dose was found for NR3C1 (p < 0.0001). Data are presented as mean ± SEM.
** p < 0.01; **** p < 0.0001; for continuous exposure: b, p < 0.05 and a, p < 0.0001 vs. control. NR3C1, Glucocorticoid receptor;
HSD11B2, 11-hydroxysteroid dehydrogenase type 2. Cell treatment was repeated at least three times.
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3.2. The Anti-Inflammatory Effect of Cortisol Was Found to Be Similar with Both Treatments;
However, Kinin Receptors Responded Differently to Each Exposure
The inflammatory genes, IL6 and IL1B, responded similarly to both treatments: the
four doses of both continuous and intermittent treatments repressed their expression
(p < 0.0001). The repression observed for IL6 was '60% and even higher for IL1B, '90%
(Figure 3A,B). Tumor necrosis factor α (TNF) was not modulated at all by both treatments
(Figure 3C). The Kallikrein-Kinin System genes, i.e., BDKRB1 and BDKRB2, which encode
the kinin B1 (B1R) and B2 (B2R) receptors, were consistently repressed by continuous
treatment (p < 0.0001 for all doses; B1R by 80–90% and B2R by '75%) (Figure 3D,E),
while the repression by intermittent treatment was less pronounced, B1R by 13–61% and
B2R by 22–51%, and dose-dependent for the B1R (Figure 3D,E).
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Figure 3. Inflammatory genes–gene expression. RT-qPCR of IL6 (A), IL1B (B), TNF (C), BDKRB1 (B1R) (D), BDKRB2 (B2R)
(E), LEP (F) and LEPR (G) in SGHPL-4 cells treated with continuous or intermittent exposure to cortisol (100, 250, 500,
1000 nM) and vehicle (0 nM) in the medium. Data were compared by two-way ANOVA with Tukey multiple comparisons
test. Interaction betwe n (continuous or intermittent) exposure to cortisol and cortisol dose was found for B1R (p < 0.0 1),
B2R (p = 0.0 6 ), and LEP (p < 0.0 1). Data re presented as mean ± SEM. * p < 0.05; * p < 0.01; * p < 0.0 1; * p < 0.0 1;
#, p = 0.9356; for continuous exposure: a, p < 0.0001 vs. control; for intermittent exposure: x, p < 0.0001 vs. control. IL6,
Interleukin 6; IL1B, Interleukin 1β; TNF, Tumor necrosis factor α; B1R, Kinin B1 receptor; B2R, Kinin B2 receptor; LEP,
Leptin; LEPR, Leptin receptor. Cell treatment was repeated at least three times.
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3.3. Continuous Treatment Modulates Leptin (LEP) and Leptin Receptor (LEPR) Expression
After continuous treatment, the three highest cortisol doses were shown to increase
the expression of LEP (250 nM, 500 nM and 1000 nM, p < 0.0001) in a dose-dependent
manner from 4.5 up to 8.3 times (Figure 3F). Despite no statistical difference was observed
in continuous exposure with 100 nM of cortisol (two-way ANOVA), LEP expression was
2.3 times higher compared to control. The expression of LEPR, which encodes the leptin
receptor (OB-R) was increased for 250, 500 and 1000 nM doses ('40%) of continuous
treatment, with no differences between them (Figure 3G). No modulation was observed for
LEP or LEPR with intermittent treatment.
3.4. Angiogenesis Pathway Genes Are Modulated by Continuous Exposure to Cortisol Even at Low
Doses. PlGF and KDR (VEGFR-2) Are Also Repressed by the Highest Dose in the
Intermittent Exposure
Continuous exposure to cortisol strongly repressed (p < 0.0001) the expression of
the angiogenesis-related genes for vascular endothelial growth factor A (VEGFA) ('47%,
Figure 4A), placental growth factor (PlGF) (24–37%, Figure 4B), and matrix metallopro-
teinase 2 (MMP2) (31–40%, Figure 4E), at almost all doses. On the other hand, intermittent
treatment modulated the expression of some of the aforementioned genes only at the
highest doses: PlGF (30–37%) and MMP2 (21–31%) (500 nM, p < 0.05; 1000 nM, p < 0.0001).
The receptor for these angiogenic factors, i.e., VEGFR-2 (KDR), which is capable of
binding to VEGF and PlGF and is responsible for the pro-angiogenic signaling pathway,
showed the opposite effect: all doses of continuous treatment increased the expression of
this receptor up to five times, while there was no modulation by intermittent treatments
(Figure 4C). Soluble VEGFR-1, encoded by an alternative transcript of the FLT1 gene (sFLT1),
an anti-angiogenic receptor that also binds to VEGF and PlGF and blocks the signaling,
was increased (p < 0.001) only with continuous treatment at 1000 nM ('70%; Figure 4D).
The sFLT1/PlGF ratio was also increased in the continuous treatment (Figure A2). No mod-
ulation was observed for MMP9 (Figure 4F).
Considering the modulations on MMP2, we also looked to other epithelial-to-mesench-
ymal transition (EMT) related genes, such as TGFβ1 and E-cadherin, but none of them were
modulated by neither continuous treatment nor higher doses of intermittent treatment
(Figure A3).
3.5. Cortisol Treatment Represses the Expression of Chemokine CXCL12 and Its Receptor
The C-X-C Motif Chemokine Ligand 12 (CXCL12) gene expression was repressed
by both treatments, although this modulation was stronger with continuous exposure to
cortisol, which repressed it by 65–74% (p < 0.0001) compared to 24–45% by the intermittent
exposure (Figure 5A). Regarding C-X-C chemokine receptor type 4 (CXCR4), all doses used
in the continuous treatment repressed gene expression (37–54%; p < 0.0001), while only the
highest dose had this effect in the intermittent treatment (42%; p < 0.05) (Figure 5B).
3.6. Cortisol Had No Impact on the Viability of the SGHPL-4 Cell Line
After analyzing the gene expression results, we speculated whether the effects pro-
moted by continuous cortisol treatment were directly related to the time and dose of the
hormone or if they could be due to cell viability, since cortisol could be interfering with cell
proliferation and survival. Therefore, the MTT assay was performed, which confirmed that
cell viability was not impacted by any treatment (Figure 6).
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3.7. Cortisol Affects Cell Migration in a Dose-Dependent Manner
EVTs are invasive cells that migrate to remodel the vessels in the maternal–fetal
interface. This characteristic depends on the degradation of the extracellular matrix and
also on the action of angiogenic growth factors, genes that have been repressed by cortisol
treatment. In order to investigate whether the protein functions were also impaired,
the wound healing assay was performed with the three highest doses of cortisol used
in continuous treatment, and cortisol was found to affect SGHPL-4 migration in a dose-
dependent manner. Figure 7 shows that the cortisol dose was directly related to the wound
healing area at the end of the experiment: the higher the dose of the hormone, the larger
the area that was not occupied by the cells.
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Figure 6. MTT assay. Cell viability assay in SGHPL-4 cells treated with the three highest doses (250,
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3.8. Cortisol Treatment Reduces the Formation of Tube-Like Structures and DBK Modulates
This Resp nse
The tube-like structures for ation assay is often used as an in vitro angiogenesis
measure to investigate the cells’ ability to form a network. This assay was performed on
matrigel in the presence of 500 nM cortisol, which is considered a physiological stress dose.
As shown in Figure 8B,D, the total number of branching points, as well as the number of
tubes, were significantly reduced after cortisol treatment compared to the control (reduced
by 33% and 24%, respectively; p < 0.05). In addition, a trend towards decrease in the
number of loops was observed (p = 0.0521; Figure 8C).
Since kinin receptors have been previously related to angiogenesis [45,46] and also
considering the response of these receptors to cortisol, the cells were treated with cortisol
and DBK, a B1R agonist. We hypothesized that DBK would improve tube formation,
but that was not observed. However, when the cells were treated with cortisol + DBK,
the B1R agonist reversed the effect promoted by cortisol (Figure 8A).
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4. Discussion
The present study showed that both intermittent and continuous treatments with corti-
sol are able to affect the SGHPL-4 trophoblast cell line. The effects of cortisol on the placental
cells have been previously investigated, but there are important peculiarities to consider,
such as cell lines (HTR8/svneo, Sw.71, BeWo, JEG3), synthetic or physiological hormone
(dexamethasone, cortisol), dose used for the treatment, and last but not least, the objective
of each investigation. Our study’s design consisted of treating SGHPL-4 EVTs with various
cortisol doses within its physiological concentration range (100–600 nmol/L) [24] in order
to analyze the differences between the same doses in different exposure patterns.
In our intermittent treatment, cortisol acted mainly as an anti-inflammatory hormone,
repressing characteristic inflammatory genes, such as IL6, IL1B and BDKRB1. Continuous
cortisol exposition, even at baseline and physiological stress doses, was capable of modu-
lating both inflammatory and angiogenic pathways, suggesting that the exposure duration
can be more relevant than the cortisol dose.
The effects of cortisol occur primarily through its binding to the glucocorticoid recep-
tor (GR), a ligand-activated transcription factor. After that, cortisol can modulate gene
transcription mainly through the interaction with the glucocorticoid response element
(GRE) or other transcription factors, increasing or decreasing the expression of target
genes [47]. In our cell treatments, continuous exposition to cortisol repressed NR3C1 for up
to 30%, while intermittent treatment did not affect the GR gene expression. This is expected
since chronic stress or inflammatory conditions requiring long-term administration of GC
can lead to repressed transcription of the NR3C1 and to resistance to glucocorticoids [48].
The hormonal levels need to be rigorously balanced during pregnancy, including cor-
tisol, which is essential for life, but can cause serious health issues when imbalanced (1, 35).
The HSD11B2 enzyme is the main player in cortisol metabolism, this enzyme converts the
bioactive cortisol into cortisone, which has much lower bioactivity and is considered the
inactive form of cortisol [49]. In both continuous and intermittent treatments, HSD11B2
was not modulated by any dose, not allowing us any inference regarding how it is being
affected. Given that HSD11B2 is responsible for cortisol to cortisone conversion, the concen-
trations of these two steroids in the supernatant would be necessary to verify whether the
activity of this enzyme has been modulated by both continuous and intermittent treatments
in EVTs or not.
Beginning with genes from inflammatory pathways, IL6 and IL1B responded similarly
to both treatments and had their expression strongly repressed. On the other hand, TNF
was not modulated in all groups from continuous and intermittent treatments, although
it was possible to observe a trend towards an increase in the highest doses of continuous
exposition. TNF as well as IL6 and IL1B are glucocorticoid-sensitive genes that classically
present a decreased transcription after cortisol exposition [50]. Since these three cytokines
are induced by nuclear factor kappa B, which can also be repressed by cortisol [48], we were
expecting a similar response profile, but it was not confirmed. Although we cannot explain
this effect, divergence in the cytokine response has been previously reported by authors
that showed modulation of IL6 and/or IL1B after stressor stimuli without modulation of
TNF in in vivo [51] and in vitro studies [52].
The inflammatory milieu is necessary for embryo implantation. IL6 together with IL1B
and BDKRB1, were the inflammatory genes most consistently repressed, and all three are
involved in important processes for pregnancy, such as modulation of protease functions
and improvement of blastocyst implantation; therefore, changes in their levels are sufficient
to impair pregnancy [53].
B1R is a receptor from the Kallikrein-Kinin System (KKS), a system widely known for
its role in inflammatory processes [54,55] that has also been described as participating in
angiogenesis [46,56]. The actions of the KKS are mediated through signaling by kinin B1
and B2 receptors, while B2R is constitutively expressed, B1R is inducible by inflammation,
however, constitutively expressed in the placenta [46,57]. In our study, the BDKRB1 and
BDKRB2 genes, which encode the B1R and B2R, respectively, were consistently repressed
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by continuous treatment, but also by intermittent treatment, albeit less pronounced. Addi-
tionally, the repression observed for B1R after intermittent exposition to cortisol was dose
dependent, which did not happen for other inflammatory genes. Besides the role of kinins
in inflammation, B1R and B2R signaling can induce VEGF and VEGFR-2 expression [56,58],
and B2R also contribute to the transactivation of VEGFR-2 through phosphorylation [59].
B1R as well as B2R and VEGFR-2 signaling increase intracellular concentrations of Ca2+
and activate endothelial NO synthase, inducing cell migration and proliferation. Kinins
have been shown to play a role in neovascularization in ischemic stress and tumor models,
however, KKS knockout animals did not seem to have physiological vascular impairments.
Despite the importance of the KKS in the process of new vessels formation, it is possible
that the KKS does not play a crucial role in embryogenesis but modulates adaptations to
ischemic stress [60], and may also be involved in the trophoblastic response to cortisol.
Lastly, in the inflammatory context, no modulation was found in LEP and LEPR
after the intermittent treatment, however, while almost all genes were repressed after
continuous exposure to cortisol, LEP expression increased in a dose-dependent manner
from 2.3 up to 8.3 times, and an increase around 40% was observed in LEPR expression.
This increase in leptin was also reported by Tzschoppe et al., 2011, who treated primary
human cytotrophoblasts with 10 µM dexamethasone for up to 72 h, and found that the
glucocorticoid incubation stimulates leptin production [61], which is also produced by
placenta during pregnancy along with adipose tissue [61,62]. Leptin is a hormone related
to the nutritional and pro-inflammatory state, but also involved in angiogenesis, healthy
pregnancy, and early human development. Basak and Duttaroy, 2012, showed that leptin
induces tube formation in first trimester EVTs, and also showed that this action was inde-
pendent of VEGF [63], one of the main angiogenic factors. Additionally, leptin promotes
trophoblast cell proliferation and survival [62]. Considering that, it is possible that the
increase we found in the expression of LEP and LEPR genes may be a response to cortisol
due to the repression we observed in genes related to angiogenic pathways to maintain
tube formation.
Regarding angiogenic factors, VEGFA and PlGF were significantly repressed by con-
tinuous exposure to cortisol, but the expression of their receptors, KDR and sFLT1, was in-
creased. While VEGFR-2 (KDR) is known to be the main receptor for the VEGF and
PlGF angiogenic signaling pathways, the soluble receptor VEGFR-1 (sFLT1) also binds
to these factors, but unlike VEGFR-2, it blocks signaling, and is therefore considered an
anti-angiogenic receptor [64]. The increased expression of both receptors may be an attempt
to compensate for the repressive effects promoted by cortisol on their ligands. Considering
intermittent treatment, even at supra-physiological doses, it did not modulate angiogenic
pathways, and for some of the evaluated genes (KDR, PlGF and MMP-2), only the highest
dose resulted in repression of mRNA expression.
Interestingly, our data are in line with the changes found in some pregnancy complica-
tions, such as intrauterine growth restriction (IUGR) and preeclampsia. The levels of sFLT1
in maternal serum are increased in preeclampsia and the sFLT1:PlGF ratio is elevated in
pregnant women before the clinical onset of preeclampsia, which is a predictive value for
this pregnancy complication [65]. In our study, the continuous treatment with cortisol
increased the sFLT1:PlGF mRNA ratio in almost all doses. Our data are also consistent with
a previous publication that showed an increased sFLT1:PlGF mRNA ratio with vitamin D
depletion in a rodent model for preeclampsia [66]. Likewise, leptin protein and mRNA
levels are also increased in the placenta of women with preeclampsia [67].
For a successful vascular uterine remodeling, matrix metalloproteinases (MMPs) are
also essential. Increases in MMP2 and MMP9 have been implicated in placentation and
physiological adaptations in a healthy pregnancy, and the expression and/or activity of
these MMPs may be altered during pregnancy complications, such as the decrease in
MMP2 and MMP9 observed in hypertensive pregnancy and preeclampsia [68]. In our
study, we did not find modulation in MMP9, but MMP2 was repressed by both continuous
(31–40%) and the highest doses of intermittent (21–31%) treatments, besides a trend towards
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decrease with the 100 nM and 250 nM doses. In early pregnancy, a low concentration of
placental MMPs may affect the spiral artery remodeling, impacting the maternal-fetal
perfusion [68]. Despite the relevance of MMP9, authors have shown that MMP2 could be
more relevant in trophoblast invasion at the initial stage of early pregnancy [69].
The inflammatory milieu is necessary for cell motility and MMP induction. Cortisol
has been shown to inhibit TGFβ1-induced EMT by others [70]. TGFβ1 inhibits trophoblastic
migration and invasiveness by increasing inhibitors of MMP2, a marker for EMT, and by
modulating E-cadherin [71]. The downregulation or repression of E-cadherin is linked
to the migratory phenotype of trophoblast cells, including EVTs [72]. Given the above,
and considering the repression found for MMP2, we hypothesized that cortisol could
contribute to an increase in TGFB1 and E-cadherin expression but neither continuous
treatment nor the higher doses of intermittent treatment modulated the expression of both
mRNAs, suggesting that the observed effects could be due to the modulatory effects of
cortisol directly on inflammatory and angiogenic markers.
Since cortisol affects inflammatory and angiogenic genes essential for embryo implan-
tation, we analyzed the chemokine CXCL12, also known as stromal cell-derived factor
(SDF)-1. This is a homeostatic chemokine that binds mainly to CXCR4, but also to CXCR7
receptors, to induce intracellular signaling essential for processes such as placentation,
implantation, and vascular remodeling in early pregnancy [73–75], in addition to inducing
trophoblast invasion and placental angiogenesis [73,76]. CXCL12-mediated signaling in
placental trophoblast cells occurs via many signaling pathways, such as ERK1/2, AKT,
p38, JAK/STAT, PI3K/AKT/FOSL1, inducing vascular growth factors and leading to the
utero-placental vascular remodeling. Placental trophoblasts, including EVTs, are the main
source of CXCL12 [73]. Regarding the effects of cortisol on this chemokine in placental
tissue or trophoblast cells, we have found no references in the literature, but other steroid
hormones, such as estradiol and progesterone, are known to decrease the expression of
CXCL12 [73]. This is in line with our findings since both continuous and intermittent
treatments with cortisol repressed CXCL12 expression, which is more accentuated with
the continuous treatment (65–74% vs. 24–45%). The continuous exposition also modulated
the expression of CXCR4 (37–54%). It is possible that continuous exposure to cortisol
represses signaling through this chemokine, which could be one of the pathways to reduce
the growth factors essential for trophoblastic function.
EVTs are invasive cells that migrate to remodel the vessels in the maternal–fetal
interface. This characteristic depends on the degradation of the extracellular matrix and
also on the action of angiogenic growth factors, genes that have been repressed by cortisol
treatment. In order to investigate whether the protein functions were also impaired,
a migration assay was performed, and cortisol was found to affect SGHPL-4 migration in
a dose-dependent manner. In addition, the difference between the effects of intermittent
and continuous exposure to cortisol was not related to cell viability, since treatments with
cortisol did not result in cell death, as assessed by the MTT assay.
Considering the cortisol effects on EVTs in the tube-like structures formation assay,
a physiological stress dose of cortisol promoted a reduction in the number of tubes, loops,
and branching points after 5h of exposure. According to previous publications, EVTs in-
vade spiral arteries and alter their phenotype, acquiring endothelial-cell like capacities,
thus promoting a network of tube-like structures [36,44,70]. Taking into account that
kinins are peptides widely known for their role in the inflammatory process [54,55] and
previously linked to angiogenesis and trophoblast function [46,56], we hypothesized that
the B1R agonist, DBK, could increase tube-formation in SGHPL-4 cells. As shown in our
results, this effect was not observed; however, when administered together with cortisol,
DBK reversed the negative effects promoted by the hormone, suggesting that B1R could
be involved in the anti-angiogenic response to cortisol. It is important to note that the
tube formation assay needs to be carefully adjusted for each cell type, and SGHPL-4 cells
show the best results within around 5 to 8 h of experiment, with almost all cells killed
within 24 h.
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Despite these relevant findings, it is important to highlight that our experiments
with SGHPL-4 as first-trimester cell line were conducted at 21% O2, and the physiological
oxygen concentration in early pregnancy is lower, 1% [77–79]. The high levels of oxygen can
provoke oxidative stress resulting in cytokine alterations and endothelial dysfunction [4,80].
Furthermore, oxygen is a regulator of trophoblast proliferation [80]. Under physiological
oxygen levels, cell function may be impacted differently by cortisol than when cultured in
hyperoxic conditions.
Considering the differences in gene modulation by distinct exposures to cortisol,
Reddy et al. [81] characterized genome-wide GR binding by combining GR binding and
gene expression data applying a range of doses (100 pM–1 mM) and times of exposure
(5 min to 4 h) to dexamethasone (DEX), a synthetic GC used to treat inflammatory diseases.
Using a lung epithelial carcinoma cell line, the authors found that up-regulated genes
were much more likely to have proximal GR binding than repressed genes (47% vs. 8%).
They also found differences in the average time for response between up- and down-
regulated genes. For the genes evaluated, 50% response occurred with 3 nM DEX, and they
also found a faster response for up-regulation, although after 1h of exposure the percentage
of total response was similar for both up-regulation and down-regulation.
The results of these kinetic experiments are in line with the findings of other au-
thors [82], who showed rapid gene induction and repression by synthetic cortisol. Given this,
we believe that the different modulations observed with continuous and intermittent expo-
sure to cortisol can be related to the repression or stimulation pathways of each target gene.
Even considering that GR stimulation involves a series of regulatory actions and multi-
farious responses, the kinetic evaluation of differences in GR occupancy and angiogenic
gene expression in trophoblast cells could improve the understanding of GC effects on
these cells. As for future investigations, we would also like to emphasize the importance
of evaluating the effects of different exposures to cortisol on epigenetic modifications in
DNA [83,84], especially during the first trimester of pregnancy [85]. The study of these
effects on gene regulation would strongly contribute to the current knowledge.
Given the above, we conclude that continuous exposure to cortisol represses inflam-
matory and angiogenic genes in a dose-dependent manner, which did not happen with
intermittent treatment, suggesting that a sustained increase in this hormone is more harm-
ful than a high short-term increase. In addition, cortisol treatment decreased cell migration
and tube formation in SGHPL-4 cells, and kinin B1 receptors inhibit this response. There-
fore, experiments evaluating the involvement of kinin receptors in the response promoted
by cortisol in the context of angiogenesis and trophoblast implantation are promising and
encouraged. Although the results presented in this study yields additional information on
the response of EVTs to the main physiological glucocorticoid, the missing protein data for
verification of the mRNA expression is a limitation of our work.
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Appendix A
Table A1. Base pair sequences of primers used in real-time PCR assays.
Gene Primers
NR3C1 For: 5
′-CGA CCA ATG TAA ACA CAT GCT-3
Rev: 5′-CCG TCC TTA GGA ACT GAA GAG-3′
HSD11B2 For: 5
′-TCA AGA CAG AGT CAG TGA GAA ACG-3′
Rev: 5′-GGA ACT GCC CAT GCA AGT G-3′
18S For: 5
′-ACA CGT TCC ACC TCA TCC TC-3′
Rev: 5′-CTT TGC CAT CAC TGC CAT TA-3′
IL6 For: 5
′-TGG CTG AAA AAG ATG GAT GCT-3′
Rev: 5′-TCT GCA CAG CTC TGG CTT GT-3′
IL1B For: 5
′-AGG GAC AGG ATA TGG AGC AAC AAG -3′
Rev: 5′-CAT CTT TCA ACA CGC AGG ACA GGT-3′
TNF For: 5
′-TGG CCC AGG CAG TCA GA-3′
Rev: 5′-GGT TTG CTA CAA CAT GG GCT ACA-3′
BDKRB1 (B1R) For: 5
′-CTG CAC AGA GTG CTG CCA ACA TT-3′
Rev: 5′-ACA CCA GAT CAG AGG CTG CCA GG-3′
BDKRB2 (B2R) For: 5
′-TCT GGC TTC TGG GCT CCG AG-3′





′-TGC TGC GGC GAT GAG AAT C-3′
Rev: 5′-CCC TTG GGT CTC CTC CTT TC-3′
KDR For: 5
′-GCA TCT CAT CTG TTA CAG C-3′
Rev: 5′-CTT CAT CAA TCT TTA CCC C-3′
sFLT1 For: 5
′-AAT CAG AGG TGA GCA CTG CAA C-3′
Rev: 5′-TGG TAC AAT CAT TCC TTG TGC TTT-3′
MMP2 For: 5
′-CCC ACT GCG GTT TTC TCG AAT-3′
Rev: 5′-CAA AGG GGT ATC CAT CGC CAT-3′
MMP9 For: 5
′-AGA CCT GGG CAG ATT CCA AAC-3′
Rev: 5′-CGG CAA GTC TTC CGA GTA GT-3′
LEP For: 5
′-CAT TGG GGA ACC CTG TGC GGA TTC-3′
Rev: 5′-TGG CAG CTC TTA GAG AAG GCC AGC-3′
LEPR For: 5
′-GTA AGA GGC TAG ATG GAC TGG GAT AT-3′
Rev: 5′-ATT CTC CAA AAT TCA GGT CCT CTC A-3′
CXCL12 For: 5
′-ATT CTC AAC ACT CCA AAC TGT GC-3′
Rev: 5′-ACT TTA GCT TCG GGT CAA TGC-3′
CXCR4 For: 5
′-GGG CAA TGG ATT GGT CAT CCT-3′
Rev: 5′-TGC AGC CTG TAC TTG TCC G-3′
TGFB1 For: 5
′-ACC AAC TAT TGC TTC AGC TC-3′
Rev: 5′-TTA TGC TGG TTG TAC AGG G-3′
E-cadherin For: 5
′-GCC ACA TAC ACT CTC TTC TC-3′
Rev: 5′-CCA TCA CAG AGG TTC CTG-3′
NR3C1, Glucocorticoid receptor; HSD11B2, Hydroxysteroid 11-Beta Dehydrogenase 2;
18S,18S ribosomal RNA; IL6, Interleukin 6; IL1B, Interleukin 1β; TNF, Tumor necrosis factor
α; B1R, Kinin B1 receptor; B2R, Kinin B2 receptor; VEGFA, Vascular endothelial growth
factor A; PlGF, Placental growth factor; KDR (VEGFR-2), Vascular endothelial growth
factor receptor 2; sFLT1 (soluble VEGFR-1), soluble Vascular endothelial growth factor
receptor 1; MMP2, Matrix metalloproteinase-2; MMP9, Matrix metalloproteinase-9; LEP,
Leptin; LEPR, Leptin receptor; CXCL12 (SDF-1), C-X-C motif chemokine ligand 12 (Stromal
cell-derived factor 1); CXCR4, C-X-C chemokine receptor type 4; TGFB1, Transforming
growth factor β1.
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Figure A1. Tube-like structures formation—a pilot experiment. Representative images of tube for-
mation (A) and the quantification of the number of tubes (B), loops (C), and branching points (D) 
of SGHPL-4 cells treated with vehicle (0 nM) or cortisol (500 nM) in the medium. Images were ob-
tained after 5 h of stimulation. Data were compared with t-test and Shapiro–Wilk test; * p < 0.05. 
Data are presented as mean ± SEM. The quantification of tubes, loops, and branching points was 
done with the WimTube Software (Wimasis, Munich, Germany). 
 
Figure A2. RT-qPCR of sFLT:PlGF ratio. sFLT1:PlGF mRNA ratio in SGHPL-4 cells treated with 
continuous exposure to cortisol (100, 250, 500, 1000 nM) and vehicle (0 nM) in the medium. Data 
were compared by Mann–Whitney test. Data are presented as mean ± SEM. * p < 0.05; ** p < 0.01; **** 
p < 0.0001. sFLT1 (soluble VEGFR-1), soluble Vascular endothelial growth factor receptor 1; PlGF, 
Placental growth factor. Cell treatment was repeated three times. 
Figure A1. Tube-like structures formation—a pilot experiment. Representative images of tube
formation (A) and the quantification of the number of tubes (B), loops (C), and branching points
(D) of SGHPL-4 cells treated with vehicle (0 nM) or cortisol (500 nM) in the medium. Images were
obtained after 5 h of stimulation. Data were compared with t-test and Shapiro–Wilk test; * p < 0.05.
Data are presented as mean ± SEM. The quantification of tubes, loops, and branching points was
done with the WimTube Software (Wimasis, Munich, Germany).
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Figure A3. RT-qPCR. TGFB1 (A) and E-cadherin (B) mRNA in SGHPL-4 cells treated with continuous 
or intermittent exposure to cortisol (100, 250, 500, 1000 nM), and vehicle (0 nM) in the medium. Data 
were compared by two-way ANOVA with Tukey multiple comparisons test. Data are presented as 
mean ± SEM. TGFB1, Transforming growth factor β1. Cell treatment was repeated three times. 
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